In Silico Simulations to Assess the In Vivo Consequences of In Vitro Metabolic Drug-drug Interactions

Recently, metabolic drug-drug interactions (M-DDI) have raised some high-profile problems in drug development resulting in restricted use, withdrawal or non-approval by regulatory agencies. The use of in vitro technologies to evaluate the potential for M-DDI has become routine in the drug development process. Nevertheless, in the absence of an integrated approach, their interpretation and value remains the subject of debate, … Continued

1 of 1
Back to top
Powered by GlobalLink OneLink Software